Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03907527 |
Recruitment Status :
Recruiting
First Posted : April 9, 2019
Last Update Posted : August 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Platinum-Resistant Fallopian Tube Carcinoma Platinum-Resistant Ovarian Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Refractory Fallopian Tube Carcinoma Refractory Ovarian Carcinoma Refractory Primary Peritoneal Carcinoma Stage III Fallopian Tube Cancer AJCC v8 Stage III Ovarian Cancer AJCC v8 Stage III Primary Peritoneal Cancer AJCC v8 Stage IIIA Fallopian Tube Cancer AJCC v8 Stage IIIA Ovarian Cancer AJCC v8 Stage IIIA Primary Peritoneal Cancer AJCC v8 Stage IIIA1 Fallopian Tube Cancer AJCC v8 Stage IIIA1 Ovarian Cancer AJCC v8 Stage IIIA2 Fallopian Tube Cancer AJCC v8 Stage IIIA2 Ovarian Cancer AJCC v8 Stage IIIB Fallopian Tube Cancer AJCC v8 Stage IIIB Ovarian Cancer AJCC v8 Stage IIIB Primary Peritoneal Cancer AJCC v8 Stage IIIC Fallopian Tube Cancer AJCC v8 Stage IIIC Ovarian Cancer AJCC v8 Stage IIIC Primary Peritoneal Cancer AJCC v8 Stage IV Fallopian Tube Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IV Primary Peritoneal Cancer AJCC v8 Stage IVA Fallopian Tube Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Primary Peritoneal Cancer AJCC v8 Stage IVB Fallopian Tube Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Primary Peritoneal Cancer AJCC v8 | Biological: PRGN-3005 UltraCAR-T cells | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 71 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase I/Ib Study Evaluating Benefit of PRGN-3005 UltraCAR-T® (Autologous CAR T Cells) in Advanced Stage Platinum Resistant Ovarian Cancer Patients |
Actual Study Start Date : | April 30, 2019 |
Estimated Primary Completion Date : | December 15, 2023 |
Estimated Study Completion Date : | November 15, 2028 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (PRGN-3005 UltraCAR-T cells) IP Administration
Patients receive autologous PRGN-3005 UltraCAR-T cells via IP administration with or without lymphodepleting chemotherapy.
|
Biological: PRGN-3005 UltraCAR-T cells
Given IP |
Experimental: Treatment (PRGN-3005 UltraCAR-T cells) IV Administration
Patients receive autologous PRGN-3005 UltraCAR-T cells via IV administration with or without lymphodepleting chemotherapy.
|
Biological: PRGN-3005 UltraCAR-T cells
Given IV |
- Incidence of adverse events [ Time Frame: Up to 12 months after infusion ]Toxicity grading will be evaluated according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 5.0 and monitoring of adverse events
- Maximal tolerated dose of PRGN-3005 [ Time Frame: Up to 28 days ]Will be determined by a 3 X 3 dose escalation study for both intraperitoneal infusion and intravenous infusion of the trial.
- Evidence of anti-tumor activity [ Time Frame: Up to 5 years ]Graded according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Diagnosed with recurrent, advanced, platinum resistant ovarian, fallopian tube, and primary peritoneal cancer that have progressed after receiving standard of care therapies or are not eligible to receive available therapies with known clinical benefit will be eligible for the study. Patients must have measurable disease that can be accurately measured in at least one dimension as >= 1.0 cm or > 1.5 cm lymph node with computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) techniques.
- Platinum resistant is defined as progression of disease within six months of platinum regimen.
- Patients with BRCA mutations who have completed standard therapies (including PARP inhibitors) are allowed on this study.
- Patients must be capable of understanding and providing a written informed consent.
- Patients must be 14 days from previous cytotoxic chemotherapy at time of cell collection.
- Laboratory values must indicate adequate organ function.
- Patients must be at least 28 days post systemic steroids prior to enrollment except as premedication for contrast allergy.
- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score of =< 2.
- Patients must have recovered from major acute infections and/or recent surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment.
- Negative serum pregnancy test for women of childbearing potential. Women of childbearing potential are those who have not been surgically sterilized, are < 60 years old, or have had menses within the past 12 months.
- Women of childbearing potential must be willing to use 2 methods of contraception before, during, and at least 4 months after the PRGN-3005 cell infusion.
Exclusion Criteria:
-
Patients with any of the following cardiac conditions:
- Symptomatic restrictive cardiomyopathy
- Unstable angina or symptomatic coronary artery disease within 4 months prior to enrollment
- New York Heart Association functional class III-IV heart failure on active treatment
- Symptomatic pericardial effusion
- Congestive heart failure
- Clinically significant hypotension.
- Patients with CA 125 =< ULN during screening.
- Patients with history of human immunodeficiency virus (HIV), West Nile, Zika, or active hepatitis B or C infections.
- Patients with severe, symptomatic ascites requiring diuretics, regular paracentesis, or other invasive interventions.
- Patients within 28 days of receiving another investigational agent.
- Patients with pulmonary hypertension, pulmonary fibrosis, or restrictive lung disease, patients with baseline oxygen saturation on room air < 92%, forced expiratory volume in 1 second (FEV1) =< 50%, or diffusion capacity of the lung for carbon monoxide (DLco) (corrected) of < 40% will be excluded.
- Women who are pregnant or breast feeding.
- Patients with second malignancy within the last 5 years excluding basal carcinoma of the skin, squamous carcinoma of the skin, or in situ cervical dysplasia that has undergone curative therapy.
- Patients with an active autoimmune disease requiring immunosuppressive therapy or uncontrolled with treatment.
- Patients who are simultaneously enrolled in any other treatment study.
- Clinical or radiological evidence of acute bowel obstruction within 30 days of enrollment.
- Patients with known or treated brain metastases.
- Patients with an active seizure disorder.
-
Any female patient who does not meet at least one of the following criteria will be considered to have reproductive potential:
- Post-menopausal for at least 12 consecutive months (i.e., no menses), or
- Undergone a sterilization procedure (hysterectomy, salpingectomy, or bilateral oophorectomy; tubal ligation is not considered a sterilization procedure). Pregnancy test for females of reproductive potential must be negative within 14 days before leukapheresis.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03907527
Contact: Amy R. Lankford, PhD | 301-556-9900 | alankford@precigen.com |
United States, Washington | |
Fred Hutch/University of Washington Cancer Consortium | Recruiting |
Seattle, Washington, United States, 98109 | |
Contact: IMTX Intake Coordinator 866-268-6129 immunotherapy@seattlecca.org | |
Principal Investigator: John Liao |
Study Director: | Amy R. Lankford, PhD | Precigen, Inc |
Responsible Party: | PGEN Therapeutics, Inc., a subsidiary of Precigen, Inc. |
ClinicalTrials.gov Identifier: | NCT03907527 |
Other Study ID Numbers: |
RG1004303 |
First Posted: | April 9, 2019 Key Record Dates |
Last Update Posted: | August 4, 2021 |
Last Verified: | July 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Platinum resistant Ovarian Cancer |
Carcinoma Ovarian Neoplasms Carcinoma, Ovarian Epithelial Fallopian Tube Neoplasms Peritoneal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Ovarian Diseases |
Adnexal Diseases Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases Gonadal Disorders Fallopian Tube Diseases Abdominal Neoplasms Digestive System Neoplasms Digestive System Diseases Peritoneal Diseases |